Zobrazeno 1 - 10
of 39
pro vyhledávání: '"Monica Bartucci"'
Publikováno v:
Frontiers in Oncology, Vol 8 (2018)
Despite substantial effort and resources dedicated to drug discovery and development, new anticancer agents often fail in clinical trials. Among many reasons, the lack of reliable predictive preclinical cancer models is a fundamental one. For decades
Externí odkaz:
https://doaj.org/article/409f1d5e3d45493eb19715398a2895d9
Autor:
Monica Bartucci, Anna C Ferrari, Isaac Yi Kim, Alexander Ploss, Martin Yarmush, Hatem E Sabaawy
Publikováno v:
Frontiers in Cell and Developmental Biology, Vol 4 (2016)
Externí odkaz:
https://doaj.org/article/7a208bcb58d141759c96f21c0278aea9
Autor:
Patrizia Vici, Simonetta Buglioni, Domenico Sergi, Laura Pizzuti, Luigi Di Lauro, Barbara Antoniani, Francesca Sperati, Irene Terrenato, Mariantonia Carosi, Teresa Gamucci, Rosanna Dattilo, Monica Bartucci, Cristina Vincenzoni, Luciano Mariani, Enrico Vizza, Giuseppe Sanguineti, Angiolo Gadducci, Ilio Vitale, Maddalena Barba, Ruggero De Maria, Marcella Mottolese, Marcello Maugeri-Saccà
Publikováno v:
PLoS ONE, Vol 11, Iss 3, p e0149872 (2016)
Cervical cancer cells commonly harbour a defective G1/S checkpoint owing to the interaction of viral oncoproteins with p53 and retinoblastoma protein. The activation of the G2/M checkpoint may thus become essential for protecting cancer cells from ge
Externí odkaz:
https://doaj.org/article/6c0932d8b3614a93a7574e82da2d2590
Autor:
Ann Zeuner, Ruggero De Maria, Mauro Biffoni, Antonio Di Virgilio, Giuseppina Zapparelli, Matilde Todaro, Daniela Martinetti, Rosanna Dattilo, Monica Bartucci
Purpose: Chemotherapy-induced apoptosis of immature hematopoietic cells is a major cause of anemia and thrombocytopenia in cancer patients. Although hematopoietic growth factors such as erythropoietin and colony-stimulating factors cannot prevent the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1f5ab242dda020f47b96ed6988b20930
https://doi.org/10.1158/1078-0432.c.6519296.v1
https://doi.org/10.1158/1078-0432.c.6519296.v1
Autor:
Hatem E. Sabaawy, Joseph Bertino, Robert S. DiPaola, Thomas W. Davis, Isaac Y. Kim, Mark N. Stein, John Kerrigan, Daniel Medina, Hua Zhong, Young-Choon Moon, Nadiya Sydorenko, Liangxian Cao, Daniel Jones, Michele Patrizii, Eric Huselid, Kathleen Flaherty, Stephani Davis, Shamila Yusuff, Monica Bartucci, Nitu Bansal
Purpose: Current prostate cancer management calls for identifying novel and more effective therapies. Self-renewing tumor-initiating cells (TICs) hold intrinsic therapy resistance and account for tumor relapse and progression. As BMI-1 regulates stem
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::925153583244741b63d2ce956090ae1f
https://doi.org/10.1158/1078-0432.c.6527079.v1
https://doi.org/10.1158/1078-0432.c.6527079.v1
Autor:
Hatem E. Sabaawy, Joseph Bertino, Robert S. DiPaola, Thomas W. Davis, Isaac Y. Kim, Mark N. Stein, John Kerrigan, Daniel Medina, Hua Zhong, Young-Choon Moon, Nadiya Sydorenko, Liangxian Cao, Daniel Jones, Michele Patrizii, Eric Huselid, Kathleen Flaherty, Stephani Davis, Shamila Yusuff, Monica Bartucci, Nitu Bansal
Supplementary data Figure S1. Functional role(s) of BMI-1 in PCa. Figure S2. BMI-1 expression in subpopulations of DU145 cells. Figure S3. Pharmacological inhibition of BMI-1. Figure S4. Molecular and cellular effects of pharmacological targeting of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4ffced9ef7f9a1c40d742ab4b16fc4aa
https://doi.org/10.1158/1078-0432.22468857
https://doi.org/10.1158/1078-0432.22468857
Autor:
Ann Zeuner, Ruggero De Maria, Mauro Biffoni, Antonio Di Virgilio, Giuseppina Zapparelli, Matilde Todaro, Daniela Martinetti, Rosanna Dattilo, Monica Bartucci
PDF file - 141KB
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d75c79a33f307d1bf6a4a76968b71168
https://doi.org/10.1158/1078-0432.22442615.v1
https://doi.org/10.1158/1078-0432.22442615.v1
Publikováno v:
Frontiers in Oncology
Frontiers in Oncology, Vol 8 (2018)
Frontiers in Oncology, Vol 8 (2018)
Despite substantial effort and resources dedicated to drug discovery and development, new anticancer agents often fail in clinical trials. Among many reasons, the lack of reliable predictive preclinical cancer models is a fundamental one. For decades
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a468899a85666e644c1625041d60ed9b
https://pubmed.ncbi.nlm.nih.gov/29484285
https://pubmed.ncbi.nlm.nih.gov/29484285
Autor:
Mona A. M. Awad, Michele Patrizii, Cindy Kui, Mervat El Ansary, Rachel A. Bigos, Eric Huselid, Kathleen Flaherty, David Augeri, Monica Bartucci, Saurabh V. Laddha, Hatem E. Sabaawy, Mohamed Hussein, S. David Kimball, John A. Gilleran
BACKGROUND: Hepatocellular carcinoma (HCC) represents one of the most lethal cancers worldwide due to therapy resistance and disease recurrence. Tumor relapse following treatment could be driven by the persistence of liver cancer stem-like cells (CSC
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d41cd91697dd658bd13f7614978bac6a
https://europepmc.org/articles/PMC7068645/
https://europepmc.org/articles/PMC7068645/
Autor:
Alfredo Pagliuca, Irene Terrenato, Marcello Maugeri-Saccà, Francesca Sperati, Rosanna Dattilo, Marcella Mottolese, Anna Di Benedetto, Patrizia Vici, Domenico Sergi, Clara Natoli, Monica Bartucci, Luigi Di Lauro, Teresa Gamucci, Maria Teresa Ramieri, Laura Pizzuti, Domenico Angelucci, Ruggero De Maria, Maddalena Barba
Publikováno v:
Scopus-Elsevier
Oncotarget
Europe PubMed Central
ResearcherID
Oncotarget
Europe PubMed Central
ResearcherID
Activation of the Hippo transducer TAZ is emerging as a novel oncogenic route in breast cancer and it has been associated with breast cancer stem cells. Additionally, TAZ expression has been linked with HER-2 positivity. We investigated the associati
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6651b57c534c19125db7b2651d2a5b2b
https://doi.org/10.18632/oncotarget.2449
https://doi.org/10.18632/oncotarget.2449